Skip to main content

Cagrilintide vs DSIP

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Cagrilintide

Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.

Full details →

DSIP

Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.

Full details →

Side-by-Side Comparison

AspectCagrilintideDSIP
MechanismActivates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1.Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties.
Typical DosageClinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically.
AdministrationSubcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use.
Side EffectsNausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.May cause grogginess upon waking, vivid dreams, or temporary headaches.
Best For

Key Differences

Unique to Cagrilintide:

Unique to DSIP:

Detailed Analysis

Commonalities

Cagrilintide and DSIP are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Cagrilintide for Fat Loss. Choose DSIP for Recovery & Healing, Sleep Quality.

Ready to Learn More?